Results 91 to 100 of about 50,964 (281)

Advanced Molecular Imaging Probes for Skeletal Diseases: Current Progress and Future Perspectives

iRADIOLOGY, EarlyView.
This review summarizes the potential molecular imaging techniques and probes for common orthopedic diseases, such as trauma, infection, metabolism, tumor, joint, spine and other fields, aiming to provide a basis for the development of a new generation of molecular imaging probes.
Shuo Guo, Yuling Cui, Zhiye Fan, Chenxin Jiang, Bowen Fu, Guangbin Cui, Yanli He   +6 more
wiley   +1 more source

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Urology Case Reports, 2020
Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223.
Masato Dobashi, Dai Kouguchi, Yukiko Kanetsuna, Junichiro Ishii   +3 more
doaj   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient with Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

, 2019
We presented a promising result of radionuclide therapy using 177Lu-PSMA and 177Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-
Elahe Pirayesh, Iraj Nabipour, Amini,, A, Hojjat Ahmadzadehfar, Esmaili,, A, Zohrabi,, F, Pirayesh,, E, Farshad Zohrabi, Jafari,, E, Nabipour,, I, Abdolhamid Esmaili, Rekabpour,, S.J, Esmail Jafari, Abdullatif Amini, Seyed Javad Rekabpour, Ahmadzadehfar,, H, Majid Assadi, Assadi,, M   +17 more
core   +1 more source

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer

, 2014
Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact
Elena Castro, David Olmos, Nuria Romero
core  

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

IJU Case Reports, 2019
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya   +3 more
doaj   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

The Prostate, EarlyView.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora, Jan Králíček, Petr Stránský Jr., Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek   +11 more
wiley   +1 more source

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study

The Prostate, EarlyView.
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma, Naoki Fujita, Shumon Kato, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Takuya Oishi, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama   +18 more
wiley   +1 more source

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions

, 2016
Orazio Caffo, Francesca Maines, Mimma Rizzo, Stefania Kinspergher, Antonello Veccia Medical Oncology Department, Santa Chiara Hospital, Trento, Italy Abstract: The treatment of elderly patients with cancer is usually viewed by clinicians as a challenge,
Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F   +4 more
core  

Isothiocyanates as Ferroptosis Inducers to Promote Cancer Cell Death

Phytotherapy Research, EarlyView.
ABSTRACT Cancer remains a leading cause of global mortality, with the therapeutic efficacy of anticancer drugs often hampered by late diagnosis and the development of chemotherapy resistance. Ferroptosis is an iron‐dependent form of regulated non‐apoptotic cell death driven by lipid peroxidation.
Valentina Citi, Renda Chahna, Francesca Maffei, Alma Martelli, Vincenzo Calderone, Carmela Fimognari, Eleonora Turrini   +6 more
wiley   +1 more source